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Background:  Older  adults  and  persons  with  chronic  conditions  are  at increased  risk for  pneumococcal
disease.  Severe  pneumococcal  disease  represents  a substantial  humanistic  and economic  burden  to  soci-
ety.  Although  pneumococcal  vaccination  (PPSV)  can  decrease  risk  for serious  consequences,  vaccination
rates  are  suboptimal.  As more  people  seek  annual  inﬂuenza  vaccinations  at  community  pharmacies,
pharmacists  have  the  ability  to identify  at-risk  patients  and  provide  PPSV.
Objectives: The  objective  of  this  study  was  to evaluate  the  impact  of  pharmacists  educating  at-risk  patients
on  the  importance  of  receiving  a pneumococcal  vaccination.
Methods: Using  de-identiﬁed  claims  from  a large,  national  pharmacy  chain,  all  patients  who  had  received
an  inﬂuenza  vaccination  between  August  1, 2010  and  November  14, 2010  and who  were  eligible for  PPSV
were  identiﬁed  for the analysis.  Based  on the Advisory  Committee  on Immunization  Practices  recom-
mendations,  at-risk  patients  were  identiﬁed  as  over  65  years  of  age  or as  aged  2–64  with  a  comorbid
conditions.  A  benchmark  medical  and  pharmacy  claims  database  of commercial  and  Medicare  health
plan  members  was  used  to derive  a PPSV  vaccination  rate  typical  of traditional  care  delivery  to  compare
to  pharmacy-based  vaccination.  Period  incidence  of  PPSV  was  calculated  and  compared.
Results: Among  the  1.3  million  at-risk  patients  who  were  vaccinated  by  a pharmacist  during  the  study
period,  65,598  (4.88%)  also received  a pneumococcal  vaccine.  This  vaccination  rate  was  signiﬁcantly
higher  than  the  benchmark  rate  of  2.90%  (34,917/1,204,104;  p <  .001)  representing  traditional  care.
Patients  aged  60–70 years  had  the  highest  vaccination  rate (6.60%;  26,430/400,454)  of any  age  group.
Conclusions: Pharmacists  were  successful  at  identifying  at-risk  patients  and  providing  additional  immu-
nization  services.  Concurrent  immunization  of  PPSV  with  inﬂuenza  vaccination  by  pharmacists  has
potential  to improve  PPSV  coverage.  These  results  support  the  expanding  role  of  community  pharmacists
in  the  provision  of wellness  and  prevention  services.. Introduction
In 2009 in the United States, invasive pneumococcal disease
IPD) is estimated to be responsible for over 44,000 cases of pneu-
onia, leading to over 5000 deaths [1]. Severe pneumococcal
isease not only causes pneumonia but also can lead to menin-
itis and septicemia [2,3]. Risk of pneumonia is especially high for
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two groups: (a) persons over age 65 years and (b) persons ages 2–64
years with chronic conditions [3]. Among these at-risk patients, the
incidence of IPD is 40 per 100,000 with a mortality rate of about 1
in 20 [4]. Furthermore, the annual direct and indirect costs of IPD
are estimated at $3.7 billion and $1.8 billion, respectively [5].
Research  has demonstrated that pneumococcal polysaccharide
vaccine (PPSV) is effective in preventing IPD [2,6–8], has a low rate
of adverse events [9], and is cost-effective [10–12]. With increased
rates of antibiotic microbial resistance, improving PPSV coverage is
the most effective strategy to prevent pneumonia-related morbid-
ity and mortality [13]. However, vaccination rates are suboptimal.
The Healthy People 2020 initiative has set two goals for PPSV cov-
Open access under CC BY-NC-ND license.erage in the United States based on age and presence of chronic
conditions [14]. For persons older than age 65 years, the target
coverage rate is 90%, from a baseline of 60% in 2008 [14]. For at-
risk persons aged 2–65 years, the target rate is 60%, from the 2008
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aseline of 17% [14]. Vaccination or immunization coverage is the
ercentage of persons in a population who have received the rec-
mmended scheduled dose of vaccine [15].
The Advisory Committee on Immunization Practices (ACIP)
eported that barriers for improving pneumococcal immunization
ere missed opportunities for vaccination (e.g., physician not sug-
esting PPSV during a routine ofﬁce visit), limited settings for
accine administration, fear of adverse events, and lack of aware-
ess of beneﬁts of PPSV [16]. A study by Klabunde et al. found
hat 47% of patients who were at risk for pneumococcal disease
ut had not received a PPSV cited, “the belief that the service was
ot needed or not knowing that it was needed” as the primary rea-
on for not being vaccinated [17]. During the past several years,
he Boards of Pharmacy in most states have changed their reg-
lations to allow pharmacists to administer both inﬂuenza and
neumococcal vaccinations [18]. Subsequently, the provision of
PSV by pharmacies has increased the number of settings for vac-
ine administration [18,19].
As  recommended by the ACIP [20], simultaneous administration
f PPSV with seasonal inﬂuenza vaccine could reduce identiﬁed
arriers to vaccination and improve PPSV coverage [21]. As more
eople seek inﬂuenza vaccinations at community pharmacies,
harmacists have the ability to identify at-risk patients, educate
hem on beneﬁts of PPSV, and provide concurrent vaccinations.
herefore, the objective of this study was to evaluate the impact
f pharmacists educating at-risk patients on the importance of
eceiving a pneumococcal vaccination. The study hypothesis was
hat PPSV coverage would be greater for patients who were identi-
ed as at-risk for IPD by pharmacists during inﬂuenza vaccination
ompared to patients in traditional care.
. Methods
When patients received inﬂuenza immunizations at a phar-
acy, the pharmacist asked patients about their risk of pneumo-
occal disease (e.g., age, smoking status, co-morbid conditions).
harmacists recommended PPSV if any risk was identiﬁed and the
atient had not previously been vaccinated. For every immuniza-
ion administered, a physician notiﬁcation letter is generated and
ither given to the patient or sent to their primary care physician.
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Pharmacy claims data, which contain vaccination records from
Walgreens’ Enterprise Data Warehouse (EDW) between November
15, 2009 and November 14, 2010, were included in the analysis.
Inﬂuenza pneumococcal vaccinations were deﬁned as pharmacy
ﬁlls for the relevant vaccinations. To focus on PPSV education con-
current with an inﬂuenza vaccination, a sample was  derived of all
patients who  had been immunized for inﬂuenza between August
1, 2010 and November 14, 2010. This sample was further lim-
ited to patients who  had evidence of at least two non-inﬂuenza
prescriptions to identify them as regular Walgreens customers
with sufﬁcient data to infer whether they had a chronic condi-
tion. Finally, because revaccination with PPSV is not recommended
within 5 years, and only four years of EDW data was available,
patients with evidence of a previous PPSV claims were excluded.
As  outlined by ACIP, at-risk patients were identiﬁed in phar-
macy claims data as aged 65 and older or as aged 2–64 with a
comorbid conditions. Comorbid conditions were deﬁned as con-
ditions identiﬁed in the ACIP recommendations for PPSV, which
included pulmonary disease, cardiovascular disease, liver disease,
anatomic asplenia, diabetes, and immune compromising condi-
tions (e.g., HIV, leukemia, malignancy). Although smoking status
was also considered at-risk per ACIP guidelines, this variable was
not available in pharmacy claims data.
To derive a comparison PPSV vaccination rate typical of tradi-
tional care delivery, Walgreens contracted with Solucia Consulting
to identify PPSV vaccinations within Solucia’s national medical and
pharmacy claims database of commercial and Medicare health plan
members. Due to medical claims lag, 2010 data were not available,
and a blended average PPSV rate was calculated based on 2008 and
2009 inﬂuenza seasons. The same inclusion and exclusion criteria
that were used to identify at-risk members in the study sample
were used to identify the benchmark sample. The hypothesis that
the PPSV vaccination rate would be higher in pharmacy-based
versus traditional care was tested using the two-proportion z-test.
3. ResultsBetween August 1, 2010 and November 14, 2010, 2,095,748
patients received inﬂuenza immunizations at Walgreens, of which
1,343,751 persons met  the ACIP recommendation for PPSV. Of
6.60%
4.89%
4.88%
8%7%6%5%4%
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hese persons at increased risk for pneumococcal disease, 921,624
atients (69%) were at-risk because they were age 65 and older.
he remaining 422,127 patients (31%) were at risk because they
ad one of the ACIP comorbid conditions and were aged 2–64.
sing similar criteria, 1,204,104 patients were found to be at-
isk for pneumococcal disease in the benchmark group. This study
roup was comprised of more women (58%, n = 776,581) than men
42%, n = 567,170). Nearly half of the study group was over age 70
ears (n = 642,222). Average age of the study group was 69 years
N = 1,343,751). The benchmark group had a similar age and gender
roﬁle ( age = 68 years; 55% female, 663,248/1,204,104).
Among the 1.3 million at-risk patients, 65,598 (4.88%) received
 pneumococcal vaccine (see Fig. 1). This vaccination rate was sig-
iﬁcantly (p < .001) higher than the PPSV benchmark rate of 2.90%
34,917/1,204,104). In the study group, PPSV rates varied by age
roup but not by gender. Patients aged 60–70 years had the highest
accination rate (6.60%, 26,430/400,454) of any age group.
.  Discussion
The rate of PPSV coverage was greater in the pharmacy patient
roup than the benchmark group representing traditional care.
oncurrent immunization of PPSV with inﬂuenza vaccination by
harmacists has potential to improve PPSV coverage. Pharmacists
ere especially effective at reaching patients aged 60–70 years,
ho are likely to be at-risk not only due to age but also due to
omorbid conditions. Further studies could be useful to elucidate
ow to reach younger at-risk persons.
No published studies were found that compared the provision
f PPSV in a community pharmacy compared to traditional care.
owever, related research inferred that pharmacist-led immuniza-
ions could improve coverage. For example, Sokos et al. [22] found
ncreased PPSV coverage after implementation of pharmacist-led
PSV screening program in an inpatient setting. Likewise, the Uni-
ersity of Wisconsin Hospital increased dual coverage of PPSV and
nﬂuenza vaccinations by 33 percentage points after implemen-
ation of pharmacy-based screening program [23]. Although not
ocused on PPSV, Loughlin et al. [24] reported that inﬂuenza cov-
rage increased by 40 percentage points after implementation of
 pharmacist-led vaccination program for cardiovascular patients.
urthermore, community pharmacies have been an effective set-
ing for screening for other preventive services [25]. The combined
vidence from the present study and the published literature sug-
ests that pharmacies are an appropriate setting for PPSV and can
e effective at improving immunization coverage.
The primary limitations of the current study were its observa-
ional design and the reliance on pharmacy claims for assessment of
overage rates. First, as with any non-randomized study, causality
annot be inferred. Second, the oldest day of EDW data available
s May  01, 2006. Because pneumonia vaccinations are generally
onsidered one-time only procedures, patients may  have received
heir vaccination at Walgreens prior to May  2006 and thus rates
epresent period incidence rather than prevalence of PPSV vaccina-
ion coverage. Furthermore, patients may  have previously received
heir PPSV vaccination elsewhere even though they obtained an
nﬂuenza vaccination at Walgreens. Inferring health conditions
rom pharmacy claims has several limitations including misclas-
iﬁcation and under-reporting. Generally, the inﬂuence of these
imitations would cause an underestimate of the PPSV vaccination
ate. Thus, the present results are a conservative estimate of the
otential impact of pharmacy-based immunization.
The results of this study suggest that pharmacists are successful
t identifying at-risk patients and providing additional immuniza-
ion services. The ability to reach patients who are 60–70 years
ld is especially salient given the high morbidity, mortality, and
[
[ (2011) 8073– 8076 8075
associated costs of IPD in this group [26,27]. With more of the
baby boomer generation reaching 65 each year, resources to meet
immunization demand in this cohort will increase [3]. Furthermore,
older patients are more likely to have multiple comorbid condi-
tions, which necessitate an integrated, coordinated care approach
[28]. Collaboration of pharmacists with primary care providers and
health systems for preventive services introduces an important
model in the era of healthcare reform [29–31]. As an effective set-
ting to engage older patients who have multiple health conditions,
pharmacies can help achieve the U.S. Department of Health and
Human Services’ Healthy People goals for vaccine coverage. This
study supports the expanding role of community pharmacists in
the provision of wellness and prevention services.
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